Abstract GS2-07: MANTA – A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer - Schmid, P; Zaiss, M; Harper-Wynne, C (Cancer Res, 2018)